News Releases

Friday, February 03, 2017

University Hospitals enters agreement with Kent State to serve as Preferred Healthcare Provider

KENT – Kent State University Athletics has formally entered into an agreement with University Hospitals (UH) as the Preferred Healthcare Provider for the Golden Flashes.
 
As the Preferred Healthcare Provider for Kent State Athletics, UH will provide a complete multi-disciplinary team of physician specialists to Kent State student-athletes.
 
“We are excited to announce this partnership with University Hospitals,” said KSU Director of Athletics Joel Nielsen. “UH is an innovator in the field of sports medicine, making an impact at all levels of athletics in our region. Student-athlete wellness is a top priority for our athletic department and our partnership with UH emphasizes our commitment to their health and safety.”
 
The agreement stipulates that UH will provide medical counsel and coverage for over 400 student-athletes who compete at Kent State. 


Friday, February 03, 2017

University Hospitals Rainbow Babies & Children’s Hospital opens first stem cell study in patients with cystic fibrosis

CLEVELAND – A 39-year-old man with cystic fibrosis (CF) made history by becoming the first person in the world to receive human adult stem cells in a new research study that researchers hope will someday lead to the development of a therapy to reduce the inflammation and infection caused by CF. 

The pioneering subject in the study is Bob Held from Alliance, Ohio, who received an infusion of cells called allogeneic human mesenchymal stem cells (hMSC), adult stem cells collected from the bone marrow of healthy volunteers.  Mr. Held was diagnosed with CF when he was 16 months old. 

Currently, there is no cure for CF, and life expectancy for patients who survive into adulthood is approximately 41 years of age.


Tuesday, January 24, 2017

National Institutes of Health honors research leaders from University Hospitals and Case Western Reserve University with prestigious Outstanding Investigator Awards

CLEVELAND – Two internationally recognized medical research leaders from University Hospitals Cleveland Medical Center and Case Western Reserve University School of Medicine have received Outstanding Investigator Awards from the National Institutes of Health (NIH). The 7-year, $6.7 million dollar awards, which are the highest honor and largest individual support grants conferred by the NIH, will advance promising molecular studies of colon cancer and age-related cardiovascular risks, respectively. The honored physicians are:
 
Sanford Markowitz, MD, PhD, head of the GI Cancer Genetics Program at the Case Comprehensive Cancer Center, Markowitz-Ingalls Professor of Cancer Genetics at Case Western Reserve University School of Medicine and medical oncologist at UH Seidman Cancer Center, received a National Cancer Institute (NCI) Outstanding Investigator Award.  


Mukesh K. Jain, MD, Chief Scientific Officer, University Hospitals and Harrington Discovery Institute; Chief Research Officer, UH Harrington Heart & Vascular Institute; Vice Dean for Medical Sciences and Professor of Medicine, Case Western Reserve University School of Medicine, received a National Heart, Lung, and Blood Institute (NHLBI) Outstanding Investigator Award. 


Wednesday, January 18, 2017

Westshore Primary Care joins University Hospitals

CLEVELAND – Sixty-three primary and specialty care providers from Westshore Primary Care joined University Hospitals on January 1, 2017. This addition is part of the acquisition of the former St. John Medical Center, the hospital now known as UH St. John Medical Center.
 
With locations in Avon, Avon Lake, Fairview Park, North Ridgeville, Rocky River, Sheffield Village and Westlake, Westshore Primary Care has served the community for more than 25 years. In addition to providing exceptional health care services in family medicine, internal medicine and pediatrics, it offers care in eight other specialties: allergy/immunology, dermatology, endocrinology, obstetrics and gynecology, midwifery, palliative care, podiatry and sports medicine.


Wednesday, January 18, 2017

Call for Scholars: Alzheimer’s Drug Discovery Foundation and Harrington Discovery Institute expand collaboration

CLEVELAND – Harrington Discovery Institute and the Alzheimer’s Drug Discovery Foundation (ADDF) are pleased to announce a request for proposals for the 2017 ADDF-Harrington Scholar Award. The ADDF-Harrington Scholar Award supports breakthrough research that promises to prevent, treat or cure Alzheimer’s disease, related dementias and cognitive aging.
 
Applicants have the opportunity to receive:
  • Financial support up to $600,000 over two years
  • Drug development and project management support through Harrington Discovery Institute’s Innovation Support Center
Research without walls: 
“This is a superb opportunity for creative researchers who seek a cure for Alzheimer’s and other dementias,” said Jonathan Stamler, MD, President, Harrington Discovery Institute and the Robert S. and Sylvia K. Reitman Family Foundation Distinguished Chair in Cardiovascular Innovation at University Hospitals and Case Western Reserve University School of Medicine. “The ADDF-Harrington partnership brings a unique combination of knowhow and resources to advance the most innovative discoveries in Alzheimer’s disease.” 
 
“Our collaboration with Harrington Discovery Institute provides Alzheimer’s researchers critical support needed to move discoveries into clinical trials,” said Howard Fillit, MD, Founding Executive Director and Chief Science Officer at the ADDF. “The impact of Alzheimer’s disease is enormous. We need new and diverse approaches to make a difference—and our partnership with Harrington Discovery Institute exemplifies our commitment to advancing these.”
 
Award criteria:
  • The competition is open to academic investigators at accredited medical centers, research institutions and universities in the United States
  • Lead investigator must have an MD or PhD (or equivalent)
  • Proposals should offer creative science or approach to treat, prevent or slow Alzheimer’s disease, other dementias or cognitive aging
 
Please note the following dates:
  • Letters of Intent will be accepted through March 17, 2017
  • Up to 3 awards will be announced by the end of October
  • Applications must be submitted online at AlzDiscovery.org/RFPs
 
 
For more information, please visit HarringtonDiscovery.org/ADDF or AlzDiscovery.org.
 



You must be logged in to view this item.



Login

This area is reserved for members of the news media. If you qualify, please update your user profile and check the box marked "Check here to register as an accredited member of the news media". Please include any notes in the "Supporting information for media credentials" box. We will notify you of your status via e-mail in one business day.